THE PROJECT ALS MISSION
Project ALS identifies and funds the most promising scientific research that will lead to the first effective treatments and a cure for ALS. We recruit the world’s best scientists and doctors to work together—rationally and aggressively—to develop a better understanding of the ALS disease process and, in parallel, better therapeutic strategies.
Project ALS is the world’s first ALS organization to focus exclusively on research. We have raised over $100 million in 22 years to fund ALS research programs at leading academic institutions including Harvard University, Columbia University, UCSF, and the Salk Institute, and have made significant progress toward a cure for ALS.
Read about the latest updates and breakthroughs in ALS research, and see the Project ALS research philosophy – something we’re proud to say has accelerated the pace of research.
@Jeanc9orf72 Thank you Jean. Given our own involvement in similar programs we'd love to discuss in more detail with you anytime - firstname.lastname@example.org if you're ever interested 🙂Read More
@Jeanc9orf72 Thanks Jean! Re: MS, the only point is that even with greater validation NfL is still not accepted as a "surrogate biomarker" in FDA' Accelerated Approval pathway. I think we agree about NfL's importance but of course it would be best if it allowed faster drug development.Read More
@Jeanc9orf72 Unfortunately even in MS, where NfL has been much longer studied than in ALS, it’s still not accepted as a surrogate. Putting that specific regulatory context aside we agree that NfL is a very promising marker & neurofilament levels should be evaluated across ALS care + trials!Read More